Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?

about

Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?

Item

http://www.wikidata.org/entity/Q50056115

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Can Interrogation of Tumour Ch ...... ents with Early Breast Cancer?

@en

Can Interrogation of Tumour Ch ...... ents with Early Breast Cancer?

@nl

type

Item

label

Can Interrogation of Tumour Ch ...... ents with Early Breast Cancer?

@en

Can Interrogation of Tumour Ch ...... ents with Early Breast Cancer?

@nl

prefLabel

Can Interrogation of Tumour Ch ...... ents with Early Breast Cancer?

@en

Can Interrogation of Tumour Ch ...... ents with Early Breast Cancer?

@nl

P1476

Can Interrogation of Tumour Ch ...... ents with Early Breast Cancer?

@en

P2093

A M Kirby

http://www.w3.org/2001/XMLSchema#string

C E Coles

http://www.w3.org/2001/XMLSchema#string

I S Bhattacharya

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials

Supervised risk predictor of breast cancer based on intrinsic subtypes

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.

Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.

Assessing the impact of a cooperative group trial on breast cancer care in the medicare population.

Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343

P304

158-165

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLON.2017.12.022

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Judith M Bliss

P5008

ScienceSource

P577

2018-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29331262

http://www.w3.org/2001/XMLSchema#string

P921

breast cancer

breast neoplasm

tumor biomarkers

P932

5821897

http://www.w3.org/2001/XMLSchema#string